ALYREF and ovarian cancer: Moreover, in ovarian cancer, ectopic ALYREF expression conferred resistance to DNA‐damaging therapeutic agents such as platinum or poly (ADP‐ribose) polymerase (PARP) inhibitors, indicating that ALYREF is a pivotal factor in regulating anti‐cancer responses.17